

## Plenary paper

# Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Teru Hideshima, Dharminder Chauhan, Yoshihito Shima, Noopur Raje, Faith E. Davies, Yu-Tzu Tai, Steven P. Treon, Boris Lin, Robert L. Schlossman, Paul Richardson, George Muller, David I. Stirling, and Kenneth C. Anderson

**Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the mechanism of its anti-MM activity is unclear. These studies demonstrate clinical activity of Thal against MM that is refractory to conventional therapy and delineate mechanisms of anti-tumor activity of Thal and its potent analogs (immunomodulatory drugs [IMiDs]). Importantly, these agents**

**act directly, by inducing apoptosis or G1 growth arrest, in MM cell lines and in patient MM cells that are resistant to melphalan, doxorubicin, and dexamethasone (Dex). Moreover, Thal and the IMiDs enhance the anti-MM activity of Dex and, conversely, are inhibited by interleukin 6. As for Dex, apoptotic signaling triggered by Thal and the IMiDs is associated with activation of related adhesion focal tyrosine kinase. These**

**studies establish the framework for the development and testing of Thal and the IMiDs in a new treatment paradigm to target both the tumor cell and the microenvironment, overcome classical drug resistance, and achieve improved outcome in this presently incurable disease. (Blood. 2000;96:2943-2950)**

© 2000 by The American Society of Hematology

## Introduction

Thalidomide (Thal) was originally used in Europe for the treatment of morning sickness in the 1950s but was withdrawn from the market in the 1960s because of reports of teratogenicity and phocomelia associated with its use. The renewed interest in Thal stems from its broad spectrum of pharmacologic and immunologic effects.<sup>1</sup> Because of its immunomodulatory and antiangiogenic effects, it has been used to effectively treat erythema nodosum leprosum, an inflammatory manifestation of leprosy.<sup>2</sup> Potential therapeutic applications span a wide spectrum of diseases, including cancer and related conditions, infectious diseases, autoimmune diseases, dermatologic diseases, and other disorders such as sarcoidosis, macular degeneration, and diabetic retinopathy.<sup>3</sup> Recent reports of increased bone marrow (BM) angiogenesis in multiple myeloma (MM),<sup>4,5</sup> coupled with the known antiangiogenic properties of Thal,<sup>6</sup> provided the rationale for its use to treat MM.<sup>7</sup> Importantly, Thal induced clinical responses in 32% of MM patients whose disease was refractory to conventional and high-dose therapy,<sup>7</sup> suggesting that it can overcome drug resistance because of its alternative mechanisms of anti-MM activity. Besides alkylating agents and corticosteroids, Thal now, therefore, represents the third distinct class of agents useful in the treatment of MM.

Given its broad spectrum of activities, Thal may be acting against MM in several ways.<sup>8</sup> First, Thal may have a direct effect on the MM cell and/or BM stromal cell to inhibit their growth and survival. For example, free radical-mediated oxidative DNA damage may play a role in the teratogenicity of Thal<sup>9</sup> and may also have anti-tumor effects. Second, adhesion of MM cells to BM stromal cells both triggers secretion of cytokines that augment MM

cell growth and survival<sup>10-12</sup> and confers drug resistance<sup>13</sup>; Thal modulates adhesive interactions<sup>14</sup> and, thereby, may alter tumor cell growth, survival, and drug resistance. Third, cytokines secreted into the BM microenvironment by MM and/or BM stromal cells, such as interleukin (IL)-6, IL-1 $\beta$ , IL-10, and tumor necrosis factor (TNF)- $\alpha$ , may augment MM cell growth and survival,<sup>12</sup> and Thal may alter their secretion and bioactivity.<sup>15</sup> Fourth, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 2 (bFGF-2) are secreted by MM and/or BM stromal cells and may play a role both in tumor cell growth and survival, as well as BM angiogenesis.<sup>5,16</sup> Given its known antiangiogenic activity,<sup>6</sup> Thal may inhibit activity of VEGF, bFGF-2, and/or angiogenesis in MM. However, Singhal et al.<sup>7</sup> observed no correlation of BM angiogenesis with response to Thal, suggesting that it may not be mediating anti-MM activity by its antiangiogenic effects. Finally, Thal may be acting against MM by its immunomodulatory effects, such as induction of a Th1 T-cell response with secretion of interferon gamma (IFN- $\gamma$ ) and IL-2.<sup>17</sup> Already 2 classes of Thal analogs have been reported, including phosphodiesterase 4 inhibitors that inhibit TNF- $\alpha$  but do not enhance T-cell activation (selected cytokine inhibitory drugs [SelCIDs]) and others that are not phosphodiesterase 4 inhibitors but markedly stimulate T-cell proliferation as well as IL-2 and IFN- $\gamma$  production (immunomodulatory drugs [IMiDs]).<sup>15</sup>

In this study, we have begun to characterize the mechanisms of activity of Thal and these analogs against human MM cells. Delineation of their mechanisms of action, as well as mechanisms of resistance to these agents, will both enhance understanding of MM disease pathogenesis and derive novel treatment strategies.

From the Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA; and Celgene Corporation, Warren, NJ.

Submitted March 8, 2000; accepted June 28, 2000.

Supported by National Institutes of Health grant PO1 78378 and the Doris Duke Distinguished Clinical Research Scientist Award (K.C.A.).

**Reprints:** Kenneth C. Anderson, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115; e-mail: [kenneth.anderson@dfci.harvard.edu](mailto:kenneth.anderson@dfci.harvard.edu).

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2000 by The American Society of Hematology

## Materials and methods

### MM-derived cell lines and patient cells

Dexamethasone (Dex)-sensitive (MM.1S) and Dex-resistant (MM.1R) human MM cell lines were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL). Doxorubicin (Dox)-, mitoxantrone (Mit)-, and melphalan (Mel)-sensitive and -resistant RPMI-8226 human MM cells were kindly provided by Dr William Dalton (Moffitt Cancer Center, Tampa, FL). RPMI-8226 cells resistant to Dox, Mit, and Mel included Dox 6 and Dox 40 cells, MR20 cells, and LR5 cells, respectively. Hs Sultan human MM cells were obtained from the American Type Culture Collection (Rockville, MD). All MM cell lines were cultured in RPMI-1640 media (Sigma Chemical, St Louis, MO) that contained 10% fetal bovine serum, 2 mmol/L L-glutamine (GIBCO, Grand Island, NY), 100 U/mL penicillin, and 100  $\mu$ g/mL streptomycin (GIBCO). Drug-resistant cell lines were cultured with either Dox, Mit, Mel, or Dex to confirm their lack of drug sensitivity. MM patient cells (96% CD38<sup>+</sup>CD45RA<sup>-</sup>) were purified from patient BM samples, as previously described.<sup>18</sup>

### Thal and analogs

Thal and analogs (Celgene, Warren, NJ) were dissolved in DMSO (Sigma) and stored at  $-20^{\circ}\text{C}$  until use. Drugs were diluted in culture medium (0.0001 to 100  $\mu\text{M}$ ) with  $< 0.1\%$  DMSO immediately before use. The Thal analogs used in this study were 4 SelCIDs (SelCIDs 1, 2, 3, and 4), which are phosphodiesterase 4 inhibitors that inhibit TNF- $\alpha$  production and increase IL-10 production from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs) but do not stimulate T-cell proliferation; and 3 IMiDs (IMiD1, IMiD2, and IMiD3), which do stimulate T-cell proliferation, as well as IL-2 and IFN- $\gamma$  secretion, but are not phosphodiesterase 4 inhibitors. The IMiDs also inhibit TNF- $\alpha$ , IL-1 $\beta$ , and IL-6 and greatly increase IL-10 production by LPS-stimulated PBMCs.<sup>15</sup>

### DNA synthesis

DNA synthesis was measured as previously described.<sup>19</sup> MM cells ( $3 \times 10^4$  cells/well) were incubated in 96-well culture plates (Costar, Cambridge, MA) in the presence of media, Thal, SelCID1, SelCID2, SelCID3, SelCID4, IMiD1, IMiD2, IMiD3, and/or recombinant IL-6 (50 ng/mL) (Genetics Institute, Cambridge, MA) for 48 hours at  $37^{\circ}\text{C}$ . DNA synthesis was measured by [<sup>3</sup>H]-thymidine (<sup>3</sup>H-TdR; NEN Products, Boston, MA) uptake. Cells were pulsed with <sup>3</sup>H-TdR (0.5  $\mu\text{Ci}$ /well) during the last 8 hours of 48-hour cultures, harvested onto glass filters with an automatic cell harvester (Cambridge Technology, Cambridge, MA), and counted by using the LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD). All experiments were performed in triplicate.

Colorimetric assays were also performed to assay drug activity. Cells from 48-hour cultures were pulsed with 10  $\mu\text{L}$  of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International Inc, Temecula, CA) to each well for 4 hours, followed by 100  $\mu\text{L}$  isopropanol that contained 0.04 HCl. Absorbance readings at a wavelength of 570 nm were taken on a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA).

### Cell cycle analysis

MM cells ( $1 \times 10^6$ ) cultured for 72 hours in media alone, Thal, IMiD1, IMiD2, and IMiD3 were harvested, washed with phosphate-buffered saline (PBS), fixed with 70% ethanol, and pretreated with 10  $\mu\text{g}/\text{mL}$  of RNase (Sigma). Cells were stained with propidium iodide (PI; 5  $\mu\text{g}/\text{mL}$ ; Sigma), and cell cycle profile was determined by using the program M software on an Epics flow cytometer (Coulter Immunology, Hialeah, FL), as in prior studies.<sup>20</sup>

### Detection of apoptosis

In addition to identifying sub-G1 cells as described above, apoptosis

in media (0.01% DMSO) or with 10  $\mu\text{mol}/\text{L}$  of Thal or 1  $\mu\text{mol}/\text{L}$  IMiD1, IMiD2, and IMiD3 at  $37^{\circ}\text{C}$  for 72 hours, with addition of drugs at 24-hour intervals. Cells were then washed twice with ice-cold PBS and resuspended ( $1 \times 10^6$  cells/mL) in binding buffer (10 mmol/L HEPES, pH 7.4, 140 mmol/L NaCl, 2.5 mmol/L CaCl<sub>2</sub>). MM cells ( $1 \times 10^5$ ) were incubated with annexin V-FITC (5  $\mu\text{L}$ ; Pharmingen, San Diego, CA) and PI (5  $\mu\text{g}/\text{mL}$ ) for 15 minutes at room temperature. Annexin V+PI- apoptotic cells were enumerated by using the Epics cell sorter (Coulter).

### Immunoblotting

MM cells were cultured with 10  $\mu\text{mol}/\text{L}$  of Thal, IMiD1, IMiD2, or IMiD3; harvested; washed; and lysed using lysis buffer: 50 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 1% Triton-X 100, 30 mmol/L sodium pyrophosphate, 5 mmol/L EDTA, 2 mmol/L Na<sub>3</sub>VO<sub>4</sub>, 5 mmol/L NaF, 1 mmol/L phenylmethyl sulfonyl fluoride (PMSF), 5  $\mu\text{g}/\text{mL}$  leupeptin, and 5  $\mu\text{g}/\text{mL}$  aprotinin. For detection of p21, cell lysates were subjected to SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membrane, and immunoblotted with anti-p21 antibody (Ab; Santa Cruz Biotech, Santa Cruz, CA). The membrane was stripped and reprobed with anti- $\alpha$  tubulin Ab (Sigma) to ensure equivalent protein loading. For detection of p53, cell lysates were prepared from MM cells ( $2 \times 10^7$ ) with the use of lysis buffer. Lysates were incubated with anti-mutant (mt) or wild-type (wt) p53 monoclonal Abs (Calbiochem, San Diego, CA) and then immunoprecipitated overnight with protein A Sepharose (Sepharose CL-4B; Pharmacia, Uppsala, Sweden). Immune complexes were analyzed by immunoblotting with horseradish peroxidase-conjugated anti-p53 Ab reactive with both mt and wt p53 (Calbiochem).

To characterize growth signaling, immunoblotting was also done with anti-phospho-specific MAPK Ab (New England Biolabs, Beverly, MA) in the presence or absence of IL-6 (Genetics Institute) and/or the MEK 1 inhibitor PD98059 (New England Biolabs), as in prior studies.<sup>21</sup> Antigen-antibody complexes were detected by using enhanced chemiluminescence (Amersham, Arlington Heights, IL). Blots were stripped and reprobed with anti-ERK2 Ab (Santa Cruz Biotech) to ensure equivalent protein loading.

To characterize apoptotic signaling, MM cells were cultured with 100  $\mu\text{mol}/\text{L}$  of Thal, IMiD1, IMiD2, or IMiD3; harvested; washed; and lysed in 1 mL of lysis buffer (50 mmol/L Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 5 mmol/L EDTA, 2 mmol/L Na<sub>3</sub>VO<sub>4</sub>, 5 mmol/L NaF, 1 mmol/L PMSF, 5  $\mu\text{g}/\text{mL}$  leupeptin, and 5  $\mu\text{g}/\text{mL}$  aprotinin), as in prior studies.<sup>22</sup> Lysates were incubated with anti-related adhesion focal tyrosine kinase (RAFTK) Ab for 1 hour at  $4^{\circ}\text{C}$  and then for 45 minutes after the addition of protein G-agarose (Santa Cruz Biotech). Immune complexes were analyzed by immunoblotting with anti-P-Tyr Ab (RC20; Transduction Laboratories, Lexington, KY) or anti-RAFTK Abs. Proteins were separated by electrophoresis in 7.5% SDS-PAGE gels, transferred to nitrocellulose paper, and analyzed by immunoblotting. The antigen-antibody complexes were visualized by chemiluminescence.

### Statistical analyses

Statistical significance of differences observed in drug-treated versus control cultures was determined by using the Student *t* test. The minimal level of significance was  $P < .05$ .

## Results

### Treatment of MM patients with Thal

Seventeen (39%) of 44 patients with MM treated at our institute responded to Thal (Table 1). This response included 6 men and 11 women. These patients had received a median of 4 (1-9) prior treatment regimens, and 10 patients had a prior high-dose therapy

**Table 1. Response to thalidomide in multiple myeloma\***


Patient	Sex†	Prior therapies	Prior stem cell transplant	Maximum change M protein‡	Duration of thalidomide therapy (mo)	Maximum daily dose thalidomide	Current status (daily thalidomide dose)
1	M	3	Yes	- 58%(PR)	8.5	200 mg	Continued response (200 mg)
2	F	5	No	- 78%(PR)	6.0	400 mg	Continued response (400 mg)
3	F	1	Yes	+ 16%(SD)	6.5	100 mg	Continued response (100 mg)
4	M	6	No	- 56%(PR)	9.0	200 mg	Continued response (200 mg)
5	F	1	No	- 62%(PR)	5.5	200 mg	Continued response (50 mg)
6	F	5	Yes	- 100%(CR)	13	500 mg	Continued response (50 mg)
7	M	9	Yes	- 54%(PR)	10	800 mg	Progressed (800 mg)
8	F	5	Yes	- 68%(PR)	4.0	200 mg	Continued response, discontinued
9	F	5	No	- 90%(PR)	7.5	400 mg	Continued response (400 mg)
10	M	5	Yes	- 9%(SD)	1.5	400 mg	Progressed
11§	F	4	Yes	- 59%(PR)	5.5	400 mg	Progressed
12§	M	4	Yes	- 64%(PR)	7.0	400 mg	Progressed
13§	F	3	Yes	- 14%(SD)	4.5	400 mg	Progressed
14§	F	2	Yes	- 55%(PR)	4.0	800 mg	Continued response (800 mg)
15	F	1	No	- 31%(SD)	6.0	400 mg	Continued response (400 mg)
16	F	1	No	- 12%(SD)	4.5	400 mg	Progressed
17	M	2	No	- 55%(PR)	6.0	200 mg	Continued response (100 mg)

\*As of January 1, 2000.

†Male (M) or female (F).

‡Partial response (PR) is  $\geq 50\%$  decrease in M protein; complete response (CR) is absence of M protein on immunofixation and normal bone marrow biopsy; stable disease (SD) is  $\leq 50\%$  decrease in M protein; progression is  $\geq 25\%$  increase in M protein or progressive clinical disease.

§Also received decadron therapy.



**Figure 1. Effect of Thal and analogs on DNA synthesis of MM cell lines and patient cells.** MM.1S (A) and Hs Sultan (B) cells were cultured with increasing concentrations (0.0001-100  $\mu\text{M}$ ) of Thal (◆), IMiD1 (■), IMiD2 (●), and IMiD3 (▲). (C) MM.1S cells were cultured with increasing concentrations (12.5-100  $\mu\text{M}$ ) of SelCID1 (◆), SelCID2 (■), SelCID3 (▲), and SelCID4 (●). In each case  $^3\text{H-TdR}$  uptake (left panels) or MTT cleavage (right panels) were measured during the last 8 and 4 hours, respectively, of 48-hour cultures. Values represent the mean ( $\pm$  SD)  $^3\text{H-TdR}$  (cpm) or

complete response (absence of monoclonal protein on immunofixation and normal BM biopsy), 11 patients achieved partial response ( $> 50\%$  decrease in monoclonal protein), and 5 patients achieved stable disease ( $< 50\%$  decrease in monoclonal protein). Patients received a median of 400 mg (range, 100-800 mg) maximum dose of daily Thal for a median of 6 months (range, 1.5-13 months). As of January 1, 2000, 11 patients have continued response at a median of 6 months (range, 4-13 months), and 6 patients have progressed at a median of 4.5 months (range, 1.5-10 months).

#### Effect of Thal and analogs on DNA synthesis by MM cell lines and patient MM cells

The effect of Thal and its analogs, including IMiD1, IMiD2, IMiD3, SelCID1, SelCID2, SelCID3, and SelCID4, on DNA synthesis of MM cell lines (MM.1S, Hs Sultan, U266, and RPMI-8226) was determined by measuring  $^3\text{H-TdR}$  uptake during the last 8 hours of 48-hour cultures, in the presence or absence of drug at various concentrations. IMiD1, IMiD2, and IMiD3 inhibited  $^3\text{H-TdR}$  uptake of MM.1S (Figure 1A) and Hs Sultan (Figure 1B) cells in a dose-dependent fashion. Fifty percent inhibition of proliferation of MM.1S cells was noted at 0.01-0.1  $\mu\text{mol/L}$  IMiD1, 0.1-1.0  $\mu\text{mol/L}$  IMiD2, and 0.1-1.0  $\mu\text{mol/L}$  IMiD3 ( $P < .001$ ). Fifty percent inhibition of proliferation of Hs Sultan cells was noted at 0.1  $\mu\text{mol/L}$  IMiD1, 1.0  $\mu\text{mol/L}$  IMiD2, and 1.0  $\mu\text{mol/L}$  IMiD3 ( $P < .001$ ). In contrast, only 15% and 20% inhibition in MM.1S and Sultan cells, respectively, were observed in cultures at even higher concentrations (100  $\mu\text{mol/L}$ ) of Thal. No significant inhibition of DNA synthesis of U266 MM cells was noted in cultures with 0.001 to 100  $\mu\text{mol/L}$  Thal or these IMiDs (data not shown). The effects of these drugs on proliferation were confirmed by using MTT assays for MM.1S cells (Figure 1A) and Hs Sultan cells (Figure 1B). Although there was also a dose-dependent inhibition of proliferation of MM.1S cells by SelCIDs, 50% inhibition was observed only at high doses (100  $\mu\text{mol/L}$ ) for only 2 of the 4 SelCIDs (SelCIDs 1 and 3, Figure 1C). Further studies,

### Effect of Thal and analogs in DNA synthesis of MM cells resistant to conventional therapy

To examine whether there was cross-resistance between Thal and the IMiDs with conventional therapies, RPMI-8226 MM cells resistant to Dox (Dox6 and Dox40 cells), Mit (MR20 cells), or Mel (LR5 cells), and MM.1R cells resistant to Dex were similarly studied. Proliferation of Dox6 and Dox40, MR20, LR5, or MM.1R cells is unaffected by culture with 60 nmol/L and 400 nmol/L Dox, 20 nmol/L Mit, 5  $\mu$ mol/L Mel, and 1  $\mu$ mol/L Dex, respectively (data not shown). Importantly,  $^3$ H-TdR uptake of Dox6, Dox40, MR20, or LR5 was inhibited in cultures with Thal and the IMiDs in a dose-dependent manner (1-100  $\mu$ mol/L) versus media alone cultures (Figure 2A-D). For example, 10  $\mu$ mol/L IMiD1 blocked proliferation of Dox6, Dox40, MR20, and LR5 cells by 20%, 33%, 32%, and 21%, respectively ( $P < .001$ ). The IMiDs similarly inhibited DNA synthesis of MM.1R cells in a dose-dependent fashion, with more than 50% inhibition at more than 1  $\mu$ mol/L IMiD1 ( $P < .001$ ; Figure 2E). These data suggest independent mechanisms of resistance to Dox, Mit, Mel, and Dex versus Thal and its analogs.


### Effect of Dex and IL-6 on response of MM cells to Thal and the IMiDs

To determine whether the effects of Thal and the IMiDs are additive with conventional therapies, we next examined the effect


of Dex (0.001-0.1  $\mu$ mol/L) together with 1  $\mu$ mol/L Thal or IMiDs on proliferation of Dex-sensitive MM.1S cells. As can be seen in Figure 3A, the IMiDs (1  $\mu$ mol/L) significantly inhibited  $^3$ H-TdR uptake of MM.1S cells (60%-75% block,  $P < .01$ ), and Dex (0.001-0.1  $\mu$ mol/L) increased this inhibition in a dose-dependent fashion. For example, doses of 0.001 to 0.01  $\mu$ mol/L Dex added to 1  $\mu$ mol/L IMiD1 increased the inhibition of proliferation by 35% relative to cultures with 1  $\mu$ mol/L IMiD1 alone ( $P < .01$ ). Given the additive effects of Dex and the IMiDs, as well as the known role of IL-6 as a growth factor and specific inhibitor of Dex-induced MM cell apoptosis,<sup>19,22,23</sup> we also examined whether exogenous IL-6 could overcome the inhibition of DNA synthesis triggered by Thal and the IMiDs. Figure 3B demonstrates that IL-6 (50 ng/mL) triggers DNA synthesis of MM.1S cells in cultures with media alone, as well as in cultures with the IMiDs (0.1 and 1  $\mu$ mol/L).

### Effect of Thal and analogs on DNA synthesis of patient MM cells

The effect of Thal and the IMiDs on DNA synthesis of patient MM cells was next examined (Figure 4). As was true for MM.1S and Hs Sultan MM cell lines,  $^3$ H-TdR uptake of patients' MM cells was also inhibited by IMiDs (0.1-100  $\mu$ mol/L) in a dose-dependent fashion, whereas the inhibitory effect of Thal, even at 100  $\mu$ mol/L, was not significant. Fifty percent inhibition of MM patient cells was observed at 100  $\mu$ mol/L (Figure 4A) and 1  $\mu$ mol/L (Figure 4B) IMiD1, respectively ( $P < .001$ ).



**Figure 2. Effect of Thal and analogs on DNA synthesis of MM cells resistant to conventional therapy.** Dox-resistant Dox6 (A) and Dox 40 (B), Mit-resistant (MR20; C), and Mel-resistant (LR5; D) cells were cultured with control media (□) or 1  $\mu$ mol/L (▨), 10  $\mu$ mol/L (▩), 100  $\mu$ mol/L (■) of Thal, IMiD1, IMiD2, or IMiD3. Values represent the mean ( $\pm$  SD)  $^3$ H-TdR (cpm) of triplicate cultures. (E) Dex-resistant MM.1R cells were cultured in control media (□) or with 0.1  $\mu$ mol/L (▨), 1  $\mu$ mol/L (▩), 10  $\mu$ mol/L (▩), or 100  $\mu$ mol/L (■) of Thal, IMiD1, IMiD2, or



**Figure 3. Effect of Dex and IL-6 on response of MM cells to Thal and the IMiDs.** (A) MM.1S cells were cultured with 1.0  $\mu$ M Thal, IMiD1, IMiD2, or IMiD3 in control media alone ( $\square$ ) or with 0.001 ( $\text{▨}$ ), 0.01 ( $\text{▩}$ ), and 0.1  $\mu$ mol/L ( $\blacksquare$ ) Dex. (B) MM.1S cells were cultured in control media alone and with 0.1 and 1.0  $\mu$ mol/L Thal, IMiD1, IMiD2, or IMiD3 either in the presence ( $\square$ ) or absence ( $\blacksquare$ ) of IL-6 (50 ng/mL). In each case,  $^3\text{H}$ -TdR uptake was measured during the last 8 hours of 48-hour cultures. Values represent the mean ( $\pm$  SD)  $^3\text{H}$ -TdR (cpm) of triplicate cultures.

#### Effect of Thal and analogs on cell cycle profile of MM cell lines and patient MM cells

To further analyze the mechanism of Thal- and IMiD-induced inhibition of DNA synthesis and to determine whether these drugs induced apoptosis of MM cells, we first examined the cell cycle profile of MM.1S, Hs Sultan cells, and patient MM cells cultured with media alone, Thal (10  $\mu$ mol/L), or the IMiDs (1  $\mu$ mol/L). Cells were harvested from 72-hour cultures and stained with PI. As shown in Figure 5A, all 3 IMiDs, and Thal to a lesser extent, increased sub-G1 MM.1S cells. Induction of apoptosis occurred at the dose-response curve noted for inhibition of proliferation. Twelve-hour cultures with Dex (10  $\mu$ mol/L) served as a positive control for triggering increased sub-G1 cells. In contrast, no increase in sub-G1 cells was observed in cultures of Hs Sultan cells or of patient MM cells with Thal or the IMiDs. Importantly, Thal and the IMiDs induced G1 growth arrest in both Hs Sultan cells and in AS patient MM cells.

To confirm these results, we performed annexin V staining of cells in these cultures. As can be seen in Figure 5B, the percentage of annexin V–positive cells in cultures of MM.1S cells with Thal, IMiD1, IMiD2, and IMiD3 was 32%, 55%, 51%, and 43%, respectively. Forty-six percent of annexin V staining was observed in cultures with Dex, whereas only 22% annexin V–positive cells were present in cultures with media alone. The percentage of


4% to 7%, respectively, under all culture conditions and was not increased by Thal or the IMiDs.

#### Effect of Thal and analogs on p21 expression in MM cell lines and patient cells

We next correlated these distinct biologic sequelae of Thal and the IMiDs with p21 status in MM.1S versus Hs Sultan and patient MM cells. As can be seen in Figure 6A, p21 expression was down-regulated by the IMiDs, as well as by Dex, in MM.1S cells; and IL-6 overcomes this inhibitory effect. In contrast, the IMiDs up-regulated p21 in Hs Sultan cells and patient MM cells. Immunoblotting with anti-tubulin Ab confirmed equivalent protein loading. Wt-p53 was recognized in MM.1S cells, whereas both wt- and mt-p53 were recognized in Hs Sultan cells and patient MM cells (Figure 6B). These studies further support the observation that Thal and the IMiDs can induce either apoptosis or G1 growth arrest in sensitive MM cells, and they are consistent with Thal and IMiD p53-mediated down-regulation of p21 and susceptibility to p53-mediated apoptosis in MM.1S cells, in contrast to induction of p21 and growth arrest in Hs Sultan cells and patient MM cells, conferring protection from apoptosis.

#### Effect of Thal and analogs on growth and apoptotic signaling in MM.1S and MM.1R cells

We have previously characterized signaling cascades mediating MM cell growth and apoptosis, as well as the antiapoptotic effect of



**Figure 4. Effect of Thal and analogs on DNA synthesis of patient MM cells.** MM cells from patient 1 (A) and patient 2 (B) were cultured with control media ( $\square$ ) or with 0.1  $\mu$ mol/L ( $\text{▨}$ ), 1.0  $\mu$ mol/L ( $\text{▩}$ ), 10  $\mu$ mol/L ( $\text{▧}$ ), and 100  $\mu$ mol/L ( $\blacksquare$ ) Thal, IMiD1, IMiD2, or IMiD3. In each case,  $^3\text{H}$ -TdR uptake was measured during the last 8 hours of 48-hour cultures. Values represent the mean ( $\pm$  SD)  $^3\text{H}$ -TdR (cpm) of triplicate

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.